The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.565
Bid: 1.53
Ask: 1.60
Change: 0.00 (0.00%)
Spread: 0.07 (4.575%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.565
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

19 May 2021 07:00

RNS Number : 0581Z
Hemogenyx Pharmaceuticals PLC
19 May 2021
 

19 May 2021

 

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

 

Director/PDMR Shareholding

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,088,120 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at an average price of 1.8288 pence per share. Following this transaction, Mr Wright has a total beneficial interest in 2,715,111 Ordinary Shares, representing approximately 0.50 per cent of the Company's issued share capital.

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

 

1.

Details of PDMR/person closely associated with them ("PCA")

a)

Name

Andrew Wright

b)

Position/status

PDMR: Financial Controller and Company Secretary

c)

Initial notification/amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares of Hemogenyx Pharmaceuticals plcIdentification code GB00BYX3WZ24

b)

Nature of the transaction

Standalone acquisition of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

GBP £0.018288

1,088,120

d)

Aggregated information

- Aggregated volume

- Price

Price(s)

Volume(s)

GBP £19,899.54

1,088,120

e)

Date of the transaction

2021-05-18

f)

Place of the transaction

London Stock ExchangeXLON

 

 

Enquiries:

 

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBRGDUDUBDGBI
Date   Source Headline
13th Nov 20179:00 amRNSPrice Monitoring Extension
13th Nov 20177:00 amRNSStatement re Press Comment
30th Oct 20177:00 amRNSLakePharma appointed for lead product development
11th Oct 20177:00 amRNSDirector/PDMR Shareholding
10th Oct 20177:00 amRNSDirector/PDMR Shareholding
5th Oct 20178:01 amRNSCornell University update
5th Oct 20178:00 amRNSAdmission & First Day of Dealings
4th Oct 201711:16 amRNSResult of General Meeting
26th Sep 20177:00 amRNSInvestor presentations
25th Sep 20177:00 amRNSHalf-year Report
11th Sep 20177:00 amRNSProposed acquisition and Placing & Subscription
13th Apr 20173:30 pmRNSFinal Results
30th Sep 20162:00 pmRNSProposed acquisition of Lime Holdings Limited
5th Aug 20167:00 amRNSInterim Report for the period ended 30 June 2016
29th Jun 20167:00 amRNSResults of Annual General Meeting
1st Jun 20169:43 amRNSPosting of Annual Report & Accounts
28th Apr 20167:00 amRNSFinal Results for period ended 31 December 2015
18th Feb 201610:33 amRNSChange of Accounting Reference Date
30th Dec 20157:00 amRNSStatement re possible acquisition
23rd Dec 201512:48 pmRNSSuspension of trading
23rd Dec 201512:45 pmRNSSuspension
18th Dec 201511:07 amRNSAppointment of Financial Advisor
7th Dec 20155:36 pmRNSStatement re: media speculation
27th Nov 20153:00 pmRNSInterim Report for the period ended 31 August 2015
25th Nov 201511:56 amRNSHolding(s) in Company
17th Nov 20153:26 pmRNSHolding(s) in Company
16th Nov 201512:47 pmRNSHolding(s) in Company
16th Nov 20157:00 amRNSAppointment of Broker
11th Nov 20155:15 pmRNSHolding(s) in Company
9th Nov 20157:00 amRNSPlacing of Shares & admission to Official List LSE

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.